Leerink Downgrades Foundation Medicine to Market Perform | GenomeWeb

NEW YORK (GenomeWeb) – Leerink today downgraded Foundation Medicine's shares following Roche's announcement that it will acquire a majority stake in the cancer genomics diagnostics firm. 

Analyst Dan Leonard downgraded Foundation to Market Perform from a previous Outperform rating, while he raised the target price on the company's shares to $50 from $30. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.